

BOOK BY 30TH NOVEMBER AND SAVE £400
BOOK BY 18TH DECEMBER AND SAVE £200
BOOK BY 29TH JANUARY AND SAVE £100

SMi present the 18th annual conference...

Superbugs & Superdrugs

Holiday Inn Kensington Forum, London, UK

16 - 17
MAR
2016

Pushing financial and collaborative incentives to accelerate clinical success

Chairs for 2016:



Richard Bax,
Senior Partner,
Transcrip Partners



Lloyd Czaplewski,
Director,
Chemical Biology Ventures Ltd

Elite International Speakers Include:

- **Line Matthiessen**, MD PhD, Head of Unit Fighting Infectious Diseases and Advancing Public Health, **European Commission**
- **Melissa Stundick**, Chief, Anti-Infectives Programme, **BARDA**
- **Ursula Theuretzbacher**, Founder, **Centre for Anti-Infective Agents**
- **Prabhavathi Fernandes**, President & CEO, **Cempra Pharmaceuticals**
- **Ankit Mahadevia**, MD, President & CEO, **Spero Therapeutics**
- **Eszter Nagy**, Co-founder, President and CSO, **Arsanis**
- **Jean de Gunzburg**, Chief Scientific Officer, **Da Volterra**
- **David Cook**, Chief Scientific Officer, **Blueberry Therapeutics**
- **Conrad Lichtenstein**, Chief Scientific Officer, **Nemesis Bioscience Ltd**
- **Steven Boakes**, Associate Director of Microbiology, **Cantab Anti-Infectives**

Key Business Benefits to Attend:

- **Network** with industry-leading experts on drug and antimicrobial material developments
- Learn new **funding** opportunities from **BARDA** and US National plans, to combat antimicrobial resistance
- Understand how the **EU Commission's** practical approach in R&D can support your business growth
- Reinvigorate business models with **Project DRIVE-AB** and find workable solutions to strengthen drug development
- Strengthen your antibiotic pipeline with new insights on microbiome profiling to fight **multi-resistant gram negative** infections
- **Hear** important discussions on tackling major bottlenecks that hinder development of new antimicrobial drugs with our **star panel line-up**

PLUS TWO INTERACTIVE HALF-DAY PRE-CONFERENCE WORKSHOPS

Tuesday 15th March 2016, Holiday Inn Kensington Forum, London, UK

WORKSHOP A

Rapid Diagnostic Tools for Infectious Diseases

Workshop Leader:

Sam Whitehouse, Chief Operating Officer, **QuantuMDx Group Ltd**
8.30am - 12.30pm

WORKSHOP B

Making a Material Difference to Healthcare

Workshop Leader:

Andrew Cross, Director, **ACT Surfaces Ltd**
1.30pm - 5.30pm

www.superbugssuperdrugs.com

Register online or fax your booking form to +44 (0) 870 9090 712 or call +44 (0) 870 9090 711



@SMIPHARM

Dear Colleagues

It is with great pleasure that we welcome you to participate in the 18th Annual Superbugs & Superdrugs conference taking place on 16th -17th March 2016, Central London, UK.

Antimicrobial resistance is clearly a serious global threat. To combat potential epidemic, requires both industry and government collaboration on an international level in antibiotics R&D investments, preventive measures and emergency response. As new resistance mechanisms rapidly spread throughout the developed and developing nations, this is putting our existing antibiotic pipeline under greater higher risk of failing to resolve many standard medical treatments, as well as compromising our achievements in modern standard medicine including cancer therapeutics and surgery. To curb an uncontrollable outbreak 'storm', we urge committed action and international stewardship from the industry to drive anti-superbugs and superdrug developments.

We are delighted to chair this annual industry meeting in 2016 again, which will gather a high level of international experts and project decision makers in a timely opportunity to discuss ongoing challenges and lay the foundation for innovations that will enhance the security and R&D projects for novel therapies in anti-infectives.

Please take time to peruse the conference agenda which has been drafted with great care to give you the very best opportunity to benchmark and learn from subject matter experts in infectious diseases, health economics and advanced technologies and solutions. Networking and learning with our peers is the secret to improving the drug development pipeline. With practical case studies and interactive roundtables, there is confidence that we will be able to crack the 'chicken or the egg' problem.

Yours Sincerely,



Richard P. Bax

Richard Bax, Senior Partner, Transcrip Partners



L. Czaplewski

Lloyd Czaplewski, Director, Chemical Biology Ventures Ltd

TWO INTERACTIVE HALF-DAY PRE-CONFERENCE WORKSHOPS Tuesday 15th March 2016, Holiday Inn Kensington Forum, London, UK

Rapid Diagnostic Tools for Infectious Diseases

8.30am – 12.30pm Workshop Leader: **Sam Whitehouse**, Chief Operating Officer, **QuantuMDx Group Ltd**

Workshop Overview:

This workshop will show attendees how complex diagnostics can be delivered in minutes for a few dollars in any setting across the globe using portable devices. We will also evaluate key definitive factors of disease diagnosis & drug resistance testing and mobile data connection.

Why you should attend:

- Gain valuable practise of understanding what factors to work with and look out for in diagnosing infections and resistant strains
- Understand the dangers of misdiagnosis and the fine lines between familiar strains and symptoms
- Learn how our models can circumvent HA's and perform in disease management and drug resistance monitoring through geo-stamped data

About the workshop leader:



Sam is chief operating officer of QuantuMDx Group Ltd and the inventor of underlying DNA extraction chemistries currently being commercialised by the company. With 14 years biotech experience including, development of cardiovascular medical devices, polymer drug systems, coating technologies, industrial research and managing a large portfolio of academic-industry biotech collaborations. Sam has a history of

commercialising basic research, licensing and technology transfer from SME's and MNC's. Currently he oversees operations in the UK, USA and Singapore.

About the Organisation:



QuantuMDx is passionate about playing a role in addressing humanitarian health challenges and strongly believes that quality molecular diagnostics is an innate human right and as such should be provided to every man, woman and child on this planet, regardless of race, country or creed.

Our mission is to develop Q-POC™ our novel handheld device to provide access to gold standard molecular diagnostic testing, in minutes, to the billions of people in poorer nations who urgently need a rapid, cheap and accurate way of diagnosing disease and drug resistance. This will help address the humanitarian health challenges such as malaria, TB, HIV and cancer and, in time, support the eradication of some diseases by prescribing the right drug, first time. Furthermore, we will develop Q-POC™ to meet the strict regulatory requirements that will enable it to become the diagnostic device of choice for all health professionals, police, rapid responders, vets and farmers.

Programme

- 8.30 Registration**
- 9.00 Opening remarks and introductions**
- 9.10 Session 1: Diagnostics**
 - Tracking emerging infections and outbreaks: Current pitfalls and areas to address
 - State-of-the-art diagnostic tools: What to measure and translate
- 9.50 Session 2: Rapid detection techniques**
 - Multiple markers in accurately diagnosing disease from broad symptoms
 - The definitive factors of diagnosing disease
- 10.30 Afternoon Tea**
- 11.00 Session 3: Mobile applications for different environments**
 - Diagnosing in different settings: Case study and evaluation
 - Data access and transfer
- 11.40 Session 4: Future work and progress**
 - Challenges of diagnosis: mutation factors and strain differentiation
 - Discussion
- 12.20 Closing remarks**
- 12.30 Close of workshop**

Making a material difference to Healthcare

1.30pm – 5.30pm Workshop Leader: **Andrew Cross**, Director, **ACT Surfaces Ltd**

Workshop Overview:

How can copper touch surfaces improve patient outcomes and provider finances? Is this a viable proposition for healthcare today? Why copper - how does copper differ from other antimicrobial surfaces? What research backs its use? Which items to consider? What products and materials are available?

Drawing on feedback and experience from previous installations, as well as current guidelines, this workshop will examine the evidence, cost-payback and practical implementation concerning the strategic deployment of copper touch surfaces.

Why you should attend:

Healthcare is under pressure to innovate, improve patient outcomes and reduce costs. This workshop explores a simple and low-risk intervention, and its potential impact on HCAI rates and Antimicrobial Resistance.

About the workshop leader:



Andrew offers a mixture of technical, practical and commercial experience, and works closely with engineers, architects / designers, construction professionals, healthcare scientists and clinical teams to prompt a reevaluation of materials used in healthcare settings.

About the Organisation:



Working in close partnership with approved suppliers and healthcare professionals, ACT Surfaces provide a comprehensive "end to end" service of advice and products. Strategic use of Antimicrobial Copper Touch Surfaces enables healthcare providers to improve patient outcomes and optimise payback. The goal is to help healthcare professionals select the right products and materials for their particular setting and infection control needs.

Programme

- 1.30 Registration**
- 2.00 Opening remarks and introductions**
- 2.10 Session 1:**
 - Two major issues in healthcare today - HCAIs and AMR
- 2.50 Session 2:**
 - The role of the patient environment in acquisition of infection and spread of AMR
- 3.30 Afternoon Tea**
- 4.00 Session 3:**
 - Evaluating Antimicrobial efficacy for touch surfaces
 - The evidence for copper
- 4.40 Session 4:**
 - Cost vs Benefit - the YHEC research
 - Q&A session, practical demonstration
- 5.20 Closing remarks**
- 5.30 Close of workshop**

Superbugs & Superdrugs

Day One | Wednesday 16th March 2016

8.30 Registration & Coffee

9.00 Chairman's Opening Remarks Richard Bax, Senior Partner, Transcrip Partners

Models for Successful Partnerships and Clinical Management

9.10 OPENING ADDRESS: Current status and future prospects

- Progress in R&D and drug regulation
- What is happening in big Pharma
- New economic models
- What needs to be done now

Richard Bax, Senior Partner, **Transcrip Partners**

9.50 Extending portfolio partnerships to strengthen the antibiotic pipeline

- Ongoing and future research and development partnerships
- BARDA's efforts to address goals in the U.S. National Plan to Combat Antibiotic Resistant infections
- Establishing a biopharmaceutical incubator to meet short and long term goals
- BARDA funding opportunities

Melissa Stundick, Chief, Anti-Infectives Programme, **BARDA**

10.30 Morning Coffee

10.50 Developing an antibiotic with potential for use in multiple therapeutic indications

- Case study: Stage 3 clinical update outcomes and response
- International collaboration for successful worldwide commercialisation

Prabhavathi Fernandes, President & CEO, **Cempra Pharmaceuticals**

11.30 Making a material difference to healthcare

- Two issues: HCAIs and AMR
- The role of touch surfaces in the acquisition of infection and spread of AMR
- Evaluation of antimicrobial efficacy
- Evidence for copper touch surfaces and YHEC payback model

Andrew Cross, Director, **ACT Surfaces Ltd**

12.10 Networking Lunch

1.10 KEYNOTE ADDRESS: Fighting global epidemics and progressing public- private partnerships

- State of play of the EU action plan on AMR
 - How is R&D being supported in a practical sense?
- Line Matthiessen**, MD PhD, Head of Unit Fighting Infectious Diseases and Advancing Public Health, **European Commission**

1.50 Project DRIVE-AB: New partners and developments

- Prioritising problem areas and future development
 - New models and action plans
 - Clinical practice strategies to aid the development pipeline
- Ursula Theuretzbacher**, Founder, **Centre for Anti-Infective Agents**

Progressive R&D and Clinical Trials

2.50 New insights of pathogen – host interactions and EU project - INFECT

- Systems medicine approach to understand pathogenic mechanisms
- New in vitro models to understand drug resistance at the tissue site of infection
- Accelerating drug development and diagnostic tools through INFECT

Anna Norrby-Teglund, Professor, Head of Center for Infectious Medicine, **Karolinska Institutet**

3.30 Afternoon Tea

4.00 Monoclonal antibody-based approaches to fight severe bacterial infections

- New paradigm to prevent and treat severe *Staphylococcus aureus* infections
- mAb products targeting MDR Gram negative infections
- Companion diagnostics for introduction of targeted therapies and support MDR infectious disease control

Eszter Nagy, Co-founder, President and CSO, **Arsanis**

4.40 Application of whole genome sequencing to public health

- Whole genome sequencing as a gold standard approach for molecular strain typing
- Outbreak investigations using whole genome sequencing
- Case study: Pattern/ type assignment
- Future perspectives in public health

Georgia Kapatai, Bioinformatician, **Public Health England**

5.20 Rapid diagnostic tools

- Advances in molecular diagnostic devices: Sample preparation and PCR
- Case study: Rapid diagnosis of drug-resistant forms of TB
- Optimising speed and accuracy for rapid detection
- Sample to result processes – fluidics and microfluidics

Sam Whitehouse, Chief Operating Officer, **QuantuMDx Group Ltd**

6.00 PANEL DISCUSSION: Tackling the major bottlenecks that hinder development of new antibacterial drugs

- Sample preparation, bottle necks in work flows
- True point of care – field based (not laboratory) testing
- Multifaceted infection control programmes and cost efficiency
- Is the biotech sector the forgotten partner in developing new treatments for AMR?
- Regulatory environment for non-traditional therapies: Is a new paradigm needed?
- Racing "The Red Queen": How can we win the arms race?
- Is giving taxpayer money to pharmaceutical companies the best way of stimulating the development of new anti-infectives?

Panel leader: Richard Bax, Senior Partner, **Transcrip Partners**
Panelists:

Prabhavathi Fernandes, President & CEO, **Cempra Pharmaceuticals**

Eszter Nagy, Co-founder, President and CSO, **Arsanis**

Sam Whitehouse, Chief Operating Officer, **QuantuMDx Group Ltd**

Conrad Lichtenstein, Chief Scientific Officer, **Nemesis Bioscience**

David Cook, Chief Scientific Officer, **Blueberry Therapeutics**

Jean de Gunzburg, Chief Scientific Officer, **Da Volterra**

6.40 Chairman's Closing Remarks and Close of Day One

8.30 Registration & Coffee

9.00 Chairman's Opening Remarks

Lloyd Czaplewski, Director, **Chemical Biology Ventures Ltd**

Strengthening the Antibiotic Pipeline

9.10 OPENING ADDRESS: What if there are no new antibiotics?

- Highlights of a review into the alternatives to antibiotics
- What can we expect within the next 10 years and how much will it cost?
- Why antimicrobial resistance must become a BIG science

Lloyd Czaplewski, Director, **Chemical Biology Ventures Ltd**

9.50 Fighting multi-resistant gram-negative infections

- Development of NCE's and combination methods that successfully penetrate the outer bacterial membrane
- Strategic collaborations that have strengthened product pipeline
- HTS and characterization of MVFR inhibitors and correlating clearance times of resistant strains with potent inhibitors

Ankit Mahadevia, MD, President & CEO, **Spero Therapeutics**

10.30 Morning Coffee

10.50 Antibiotic resurrection: Taking the path of least resistance

- Achieving antibiotic sensitivity and resistance prevention
- Nemesis Symbiotics: Delivery options for companion therapeutics
- Clinical applications

Conrad Lichtenstein, Chief Scientific Officer,
Nemesis Bioscience Ltd

11.30 Building a pipeline and framework for developing novel anti-microbial drugs

- Are there opportunities beyond small molecule antibiotics?
- Building partnerships and collaborations to drive innovation
- Challenges
- Economics: The elephant in the room?

David Cook, Chief Scientific Officer, **Blueberry Therapeutics Ltd**

12.10 Networking Lunch

1.10 Clinical development of broad-spectrum anti-infective treatment drugs

- Protecting the human microbiome – what do we know? New frontiers microbiome profiling
- Narrow spectrum vs broad-spectrum antibiotics on the microbiome
- Pre-clinical to clinical trial evaluation

Jean de Gunzburg, Chief Scientific Officer, **Da Volterra**

1.50 Determining preclinical PK/PD relationships for faster and accurate drug development

- Efficiently modelling PK and PD for optimising dosage requirements of new and existing drugs
- Regulatory recommendations of PK/PD relationships for antibacterial agents
- Preclinical models of PK/PD results and human translatability
- Individualised treatment and controlling extreme variability

William Hope, Professor, Antimicrobial Pharmacodynamics and Therapeutics, **University of Liverpool**

Smart Antimicrobials and Pioneering Approaches

2.30 Antimicrobial peptides as viable alternatives

- Pros and Cons of antimicrobial peptides
- Current pipeline
- Cantab Anti-infectives experience with lantibiotics and polymyxins.

Steven Boakes, Associate Director of Microbiology,
Cantab Anti-Infectives

3.10 Afternoon Tea

3.30 The use of combination antibiotic therapy

- History of antibiotic combinations
- Rationale for combination therapy
- Advantages / disadvantage of combining antibiotics
- Testing regimens for combination therapy

William Weiss, Director, Pre-Clinical Services,
UNT Health Science Center

4.10 Hyperbaric oxygen treatment as an adjunctive treatment to infectious diseases and its synergistic effects

- Mechanisms of HBO₂ therapy in underpinning improved immunity and increased antibiotic activity
- A retrospective analysis of patients who received HBO treatment and outcomes
- Synergistic effects to improve clinical outcomes in patients post-surgery

Ole Hyldegaard, Medical Director, Associate Professor,
University Hospital of Copenhagen-Rigshospitalet

4.50 Microbiota host interactions as a starting point for antimicrobial strategies


- Experimental microbiota platforms
- Next generation sequencing
- Analysing AMR development through metagenomics
- Host pathogen/microbiome interactions

Frank Schuren, Senior Scientist Microbiology, **TNO**


5.20 Chairman's Closing Remarks and Close of Day Two

Superbugs and Superdrugs

2015 Attendee Profile by Sector



2015 Attendee Profile by Job Function



SMi Pharmaceutical 2016 Planner:

JANUARY

Pharmaceutical Microbiology

20th - 21st January 2016
Holiday Inn Kensington Forum,
London, UK

Social Media In The Pharmaceutical Industry

20th - 21st January 2016
Holiday Inn Kensington Forum,
London, UK

Pre-Filled Syringes

27th - 28th January 2016
Coptthorne Tara Hotel,
London, UK

FEBRUARY

Parallel Trade

8th - 9th February 2016
Holiday Inn Kensington Forum,
London, UK

Advances and Progress in Drug Design

15th - 16th February 2016
Holiday Inn Kensington Forum,
London, UK

RNAi Therapeutics

15th - 16th February 2016
Holiday Inn Kensington Forum,
London, UK

MARCH

Superbugs & Superdrugs - A Focus on Antibacterials

16th - 17th March 2016
Holiday Inn Kensington Forum,
London, UK

Paediatric Clinical Trials

16th - 17th March 2016
Holiday Inn Kensington Forum,
London, UK

APRIL

Asthma & COPD

11th - 12th April 2016
Holiday Inn Kensington Forum,
London, UK

Controlled Release

18th - 19th April 2016
Holiday Inn Regents Park,
London, UK

Adaptive Designs

18th - 19th April 2016
Holiday Inn Regents Park,
London, UK

Pre Filled Syringes USA

25th - 26th April 2016
Renaissance Woodbridge,
New Jersey, USA

Lyophilisation USA

27th - 28th April 2016
Renaissance Woodbridge,
New Jersey, USA

SPONSORSHIP AND EXHIBITION OPPORTUNITIES

SMi offer sponsorship, exhibition, advertising and branding packages, uniquely tailored to complement your company's marketing strategy. Prime networking opportunities exist to entertain, enhance and expand your client base within the context of an independent discussion specific to your industry. Should you wish to join the increasing number of companies benefiting from sponsoring our conferences please call:

Alia Malick on +44 (0) 20 7827 6168 or email: amalick@smi-online.co.uk

Official Media Partners



Official Publications



Supported by



Want to know how you can get involved? Interested in promoting your services to this market?

Contact Teri Arii, SMi Marketing on +44 (0) 207 827 6162 or email: teriarri@smi-online.co.uk

SUPERBUGS & SUPERDRUGS

Conference: Wednesday 16th & Thursday 17th March 2016, Holiday Inn Kensington Forum, London, UK

Workshops: Tuesday 15th March 2016, London, UK

4 WAYS TO REGISTER

www.superbugssuperdrugs.com

FAX your booking form to +44 (0) 870 9090 712

PHONE on +44 (0) 870 9090 711

POST your booking form to: Events Team, SMi Group Ltd, 2nd Floor

South, Harling House, 47-51 Great Suffolk Street, London, SE1 0BS, UK

EARLY BIRD DISCOUNT

- ☐ Book by 30th November 2015 to receive £400 off the conference price
- ☐ Book by 18th December 2015 to receive £200 off the conference price
- ☐ Book by 29th January 2016 to receive £100 off the conference price

Unique Reference Number

Our Reference

LVP-163

DELEGATE DETAILS

Please complete fully and clearly in capital letters. Please photocopy for additional delegates.

Title: Forename:

Surname:

Job Title:

Department/Division:

Company/Organisation:

Email:

Company VAT Number:

Address:

Town/City:

Post/Zip Code: Country:

Direct Tel: Direct Fax:

Mobile:

Switchboard:

Signature: Date:

I agree to be bound by SMi's Terms and Conditions of Booking.

ACCOUNTS DEPT

Title: Forename:

Surname:

Email:

Address (if different from above):

Town/City:

Post/Zip Code: Country:

Direct Tel: Direct Fax:

VENUE

Holiday Inn Kensington Forum, 97 Cromwell Rd, London SW7 4DN, UK

☐ Please contact me to book my hotel

Alternatively call us on +44 (0) 870 9090 711.

email: events@smi-online.co.uk or fax +44 (0) 870 9090 712

Terms and Conditions of Booking

Payment: If payment is not made at the time of booking, then an invoice will be issued and must be paid immediately and prior to the start of the event. If payment has not been received then credit card details will be requested and payment taken before entry to the event. Bookings within 7 days of event require payment on booking. Access to the Document Portal will not be given until payment has been received.

Substitutions/Name Changes: If you are unable to attend you may nominate, in writing, another delegate to take your place at any time prior to the start of the event. Two or more delegates may not 'share' a place at an event. Please make separate bookings for each delegate.

Cancellation: If you wish to cancel your attendance at an event and you are unable to send a substitute, then we will refund/credit 50% of the due fee less a £50 administration charge, providing that cancellation is made in writing and received at least 28 days prior to the start of the event. Regrettably cancellation after this time cannot be accepted. We will however provide the conference documentation via the Document Portal to any delegate who has paid but is unable to attend for any reason. Due to the interactive nature of the Briefings we are not normally able to provide documentation in these circumstances. We cannot accept cancellations of orders placed for Documentation or the Document Portal as these are reproduced specifically to order. If we have to cancel the event for any reason, then we will make a full refund immediately, but disclaim any further liability.

Alterations: It may become necessary for us to make alterations to the content, speakers, timing, venue or date of the event compared to the advertised programme.

Data Protection: The SMi Group gathers personal data in accordance with the UK Data Protection Act 1998 and we may use this to contact you by telephone, fax, post or email to tell you about other products and services. Unless you tick here ☐ we may also share your data with third parties offering complementary products or services. If you have any queries or want to update any of the data that we hold then please contact our Database Manager databasemanager@smi-online.co.uk or visit our website www.smi-online.co.uk/updates quoting the URN as detailed above your address on the attached letter.

CONFERENCE PRICES

I would like to attend: (Please tick as appropriate)

☐ Conference & 2 Workshops	Fee	Total
☐ Conference & 1 Workshop AM ☐ PM ☐	£2697.00 + VAT	£3236.40
☐ Conference only	£2098.00 + VAT	£2517.60
☐ 1 Workshop only AM ☐ PM ☐	£1499.00 + VAT	£1798.80
☐ 2 Workshops	£599.00 + VAT	£718.80
	£1198.00 + VAT	£1437.60

PROMOTIONAL LITERATURE DISTRIBUTION

- ☐ Distribution of your company's promotional literature to all conference attendees
- | | | |
|---------|-------|----------|
| £999.00 | + VAT | £1198.80 |
|---------|-------|----------|

The conference fee includes refreshments, lunch, conference papers, and access to the Document Portal. Presentations that are available for download will be subject to distribution rights by speakers. Please note that some presentations may not be available for download. Access information for the document portal will be sent to the e-mail address provided during registration. Details are sent within 24 hours post conference.

DOCUMENTATION

I cannot attend but would like to purchase access to the following Document Portal/paper copy documentation

	Price	Total
☐ Access to the conference documentation on the Document Portal	£499.00 + VAT	£598.80
☐ The Conference Presentations – paper copy (or only £300 if ordered with the Document Portal)	£499.00 -	£499.00

PAYMENT

Payment must be made to **SMi Group Ltd**, and received before the event, by one of the following methods **quoting reference P-163 and the delegate's name**. Bookings made within 7 days of the event require payment on booking, methods of payment are below. Please indicate method of payment:

- ☐ **UK BACS** Sort Code **300009**, Account **00936418**
- ☐ **Wire Transfer** Lloyds TSB Bank plc, 39 Threadneedle Street, London, EC2R 8AU
Swift (BIC): **LOYDGB21013**, Account **00936418**
IBAN **GB48 LOYD 3000 0900 9364 18**
- ☐ **Cheque** We can only accept Sterling cheques drawn on a UK bank.
- ☐ **Credit Card** ☐ Visa ☐ MasterCard ☐ American Express
- All credit card payments will be subject to standard credit card charges.

Card No:

Valid From / / Expiry Date / /

CVV Number 3 digit security on reverse of card, 4 digits for AMEX card

Cardholder's Name:

Signature: Date:

I agree to be bound by SMi's Terms and Conditions of Booking.

Card Billing Address (if different from above):

If you have any further queries please call the Events Team on tel +44 (0) 870 9090 711 or you can email events@smi-online.co.uk